Dexcom rises after quarterly sales beat estimates
View all comments(0)
Shares of medical device maker Dexcom DXCM.O rise 3.9% to $72.98 premarket
Late on Thursday, co posted Q1 sales of $1.04 bln, above analysts' est of $1.02 bln - LSEG
Co reiterated its annual sales forecast of $4.60 bln; analysts were expecting 2025 sales of $4.61 bln - LSEG
J.P.Morgan analyst Robbie Marcus said the co has taken a "conservative approach" and expects to see "outperformance over the balance of the year"
Co reports Q1 adj profit of 32 cents/share, compared with est of 33 cents/share - LSEG
As of last close, stock down 9.7% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.